Email this article Clinicomorphological assessment of budesonide efficiency in patients with bronchial asthma
- Authors: Budkova AA1, Volkova LI1, Budkov SR1, Bogomyagkov VS1
-
Affiliations:
- Issue: Vol 78, No 8 (2003)
- Pages: 48-51
- Section: Editorial
- URL: https://ter-arkhiv.ru/0040-3660/article/view/33372
- ID: 33372
Cite item
Full Text
Abstract
Aim, To study clinicomorphological efficacy of inhalation glucocorticosteroid budesonide (benacort,
Pulmomed, Russia) in bronchial asthma.
Material and methods. Twenty patients with bronchial asthma were treated with budesonide.
Results. A response to budesonide was manifest to the end of treatment week 1. Budesonide reduced
frequency of acute asthma episodes and the need in inhalations of short-acting $2-agonists. The peak
expiratory velocity (PEV) rose by 12% in three months, variability of PEV lowered by 13%, in 6
months by 21%o, in 12 months by 31% compared to pretreatment values. In 12 months hypersecretion
and thickness of basal membrane decreased. Three-month treatment also reduced eosinophil and lymphocyte
epithelial count and cell density of stromal infdtrate in bronchial mucosa. In 12 months cell
density of stromal infdtrate diminished.
Conclusion. Bronchial asthma treatment with budesonide for 12 months reduces 24 hour rate of acute
asthma episodes, the need in the disease exacerbations, improves functional indices of respiration but
morphological composition of bronchial mucosa does not normalize completely this showing the necessity
of longer budesonide administration
Pulmomed, Russia) in bronchial asthma.
Material and methods. Twenty patients with bronchial asthma were treated with budesonide.
Results. A response to budesonide was manifest to the end of treatment week 1. Budesonide reduced
frequency of acute asthma episodes and the need in inhalations of short-acting $2-agonists. The peak
expiratory velocity (PEV) rose by 12% in three months, variability of PEV lowered by 13%, in 6
months by 21%o, in 12 months by 31% compared to pretreatment values. In 12 months hypersecretion
and thickness of basal membrane decreased. Three-month treatment also reduced eosinophil and lymphocyte
epithelial count and cell density of stromal infdtrate in bronchial mucosa. In 12 months cell
density of stromal infdtrate diminished.
Conclusion. Bronchial asthma treatment with budesonide for 12 months reduces 24 hour rate of acute
asthma episodes, the need in the disease exacerbations, improves functional indices of respiration but
morphological composition of bronchial mucosa does not normalize completely this showing the necessity
of longer budesonide administration
References
- Метод оптимизации антиастматической терапии / Чучалин А. Г., Антонов Н. С, Сахарова Г. М. и др. М.: 1997.12-17.
- Bateman Т. D., Bousquet J., Braunstein G. L. Is overall asthma control being achieved? A hypothesis-generating study. Eur. Respir. J. 2001; 17(4): 589-595
- Hoshino M., Nakamura Y. Anti-inflammatory effects of inhaled beclomethasone dipropionate in nonatopic asthmatics. Ibid. 1996; 9(4): 696-702.
- Jeffery P. K. Pathology of asthma. Br. Med. Bull. 1992; 48(1): 23-39.
- Кахновский И. М., Соломатин А. С. Беклометазона дипропионат, будесонид и флунизолид в лечении бронхиальной астмы. Тер. арх. 1995; 3: 34-38.
- Bardin P. G., Johnston S. L., Holgate S. Т. Anti-inflammatory for the treatment of asthma. S. Afr. Med. J. 1992; 81(6): 303- 309.
- Burke С. M., Sreenan S., Pathmakauthan S. et al. Relative effects of inhaled corticosteroids on immunopathology and physiology in asthma: a controlled study. Thorax 1996; 51(10): 993-999.
- Barnes P. J. Current issues for establishing inhaled corticosteroids as the anti-inflammatory choice in asthma. J. Allergy. Clin. Immunol. 1998; 101(4, pt. 2): 427-433.
- Burke C., Power С. К., Norris A. et al. Lung function and immumopathological changes affer inhaled corticosteroid therapy in asthma. Eur. Respir. J. 1992; 1(1): 73-79.
- Djukanovic R., Wilson J. W., Lai С. К. W. et al. The safety aspects of fiberoptic bronchoscopy, bronchoalveolar lavage, and endobronchial biopsy in asthma. Am. Rev. Respir. Dis. 1992; 143: 772-777.
- Taylor J. K. Fluticasone propionate in the treatment of asthma exacerbations. Eur. Respir. Rev. 1997; 7(49): 344-348.
Supplementary files
